Formulations of a Bruton's tyrosine kinase inhibitor
Granted 23 Oct 2018 · 1 office action
Current assignee: Pharmacyclics · originally AbbVie Inc.
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Harisha Atluri, Alexander Jacob McVey, Ching Wah Chong, Robert Kuehl +4 · Examiner: Nizal S Chandrakumar · AU 1625 · TC 1600
Life of the application
8 dated eventsAbstract
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Claims as granted
25 claimsLog in to read the claims of this application.
Log in to unlockClassifications
9 codes- A61K9/20
- A61K47/38
- A61K47/26
- A61K47/02
- A61K47/12
- A61K9/10
- A61K9/16
- A61K9/14
- A61K31/519
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this application are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockDocuments
Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.
Log in to unlockChain of title
No assignments have been recorded for this application yet.